Atom Investors’s ResMed RMD Stock Holding History

Atom Investors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,009	Closed	-$346K	–	657
2023 Q4	$346K	Sell	2,009 -1,826	-48%	-$281K	0.06%	339
2023 Q3	$567K	Buy	+3,835	New	+$693K	0.13%	210
2020 Q4	–	Sell	-4,576	Closed	-$784K	–	536
2020 Q3	$784K	Buy	+4,576	New	+$845K	0.07%	218
2019 Q4	–	Sell	-2,307	Closed	-$312K	–	297
2019 Q3	$312K	Sell	2,307 -699	-23%	-$91.6K	0.02%	241
2019 Q2	$367K	Sell	3,006 -10,597	-78%	-$1.17M	0.02%	327
2019 Q1	$1.41M	Buy	+13,603	New	+$1.4M	0.12%	153

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Atom Investors's RMD Position: Q1 2024 in Review

Atom Investors sold out of ResMed (RMD) in Q1 2024, closing a stake of 2,009 shares — an estimated $346K sold.

Atom Investors first reported a position in RMD in Q1 2019 and held it in 6 quarters. The position peaked at $1.41M in Q1 2019. 718 funds tracked by Wall St. Rank hold RMD as of Q1 2024.

Atom Investors reported no remaining ResMed position as of Q1 2024 after selling out during the quarter.
Atom Investors sold 2,009 ResMed shares in Q1 2024, an estimated $346K.
Atom Investors first reported a position in ResMed in Q1 2019 and held it in 6 quarters.
Atom Investors's ResMed position peaked at $1.41M in Q1 2019.
718 funds tracked by Wall St. Rank held ResMed as of Q1 2024.

Based on Atom Investors's 13F filing for Q1 2024, filed 15 May 2024.